Skip to main content
SpringerLink
Log in

The Role of Systemic Chemotherapy

  • Chapter
Treatment of Peritoneal Surface Malignancies

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 892 Accesses

Abstract

Development of peritoneal carcinomatosis (PC) in metastatic solid tumors is associated with poor prognosis and is usually more frequent in gynecological and gastrointestinal (GI) malignancies. No standard systemic or local treatment can eradicate PC definitively, and chemotherapy (CHT) and surgery alone seem unable to improve patient survival, so that PC is usually considered a terminal condition [1]. PC is commonly observed in ovarian cancer (OC), in which the spread of disease is primarily locoregional and then to visceral sites. In this pathology, complete PC removal is associated with improved survival. In GI tumors, such as gastric and colorectal cancer (CRC), PC is seen less frequently, and its cytoreduction is not considered mandatory due to the high percentage of short-term recurrence and no effect on survival rates [2]. Systemic CHT has a limited impact on the peritoneum, probably because the peritoneal cavity is a “pharmacological sanctuary” in which intravenously administered drug diffusion is difficult. This is due to a blood-peritoneal barrier, composed of stromal tissues between mesothelial and endothelial cells, of ∼90-μm thickness, which is difficult to overcome by many systemic agents [3]. Given this low effectiveness of systemic therapies or surgery alone and the necessity to improve the local action of drugs, in recent decades, new multimodal approaches have been developed based on the association of cytoreductive surgery (CRS) with intravenous (IV) (neoadjuvant or adjuvant) and/or intraperitoneal (IP) administration of CHT (IP-CHT). Different combinations and integrations of these treatments have been proposed and evaluated in randomized or nonrandomized trials in many cancer types.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chu DZ, Lang NP, Thompson C et al (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364–367

    Article  CAS  PubMed  Google Scholar 

  2. Coccolini F, Gheza F, Lotti M et al (2013) Peritoneal carcinomatosis. World J Gastroenterol 19:6979–6994

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Jacquet PH, Sugarbaker PH (1996) Peritoneal-plasma barrier. In: Sugarbaker PH, editor. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic Publisher, pp 53–63

    Chapter  Google Scholar 

  4. Sugarbaker PH, Mora JT, Carmignani P et al (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10:112–122

    Article  CAS  PubMed  Google Scholar 

  5. Los G, Mutsaers PH, van der Vijgh WJ et al (1989) Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380–3384

    CAS  PubMed  Google Scholar 

  6. Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12:689–701

    Article  PubMed  Google Scholar 

  7. Mohamed F, Marchettini P, Stuart OA et al (2003) Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 10:463–468

    Article  PubMed  Google Scholar 

  8. Roviello F, Caruso S, Marrelli D et al (2011) Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. G Chir 32:211–233

    CAS  PubMed  Google Scholar 

  9. http://medstarhealthphysicians.org/body.cfm?id=559148

    Google Scholar 

  10. Bakrin N, Bereder JM, Decullier E et al (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 9:1435–1443

    Article  Google Scholar 

  11. Gervais MK, Dubè P, McConnell Y et al (2013) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. J Surg Oncol 108:438–443

    Article  CAS  PubMed  Google Scholar 

  12. Eveno C, Passot G, Goéré D et al (2013) Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin. Ann Surg Oncol [Epub ahead of print]

    Google Scholar 

  13. Franko J, Ibrahim Z, Gusani NJ et al (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756–3762

    Article  PubMed  Google Scholar 

  14. Randall TC, Rubin SC (2001) Cytoreductive surgery for ovarian cancer. Surg Clin North Am 81:871–883

    Article  CAS  PubMed  Google Scholar 

  15. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–200

    Article  CAS  PubMed  Google Scholar 

  16. Du Bois A, Lück H-J, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1330

    Article  PubMed  Google Scholar 

  17. Alberts DS, Liu DY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 335:1950–1955

    Article  CAS  PubMed  Google Scholar 

  18. Markman M, Bundi BM, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an inter-group study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    CAS  PubMed  Google Scholar 

  19. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  20. Landrum LM, Java J, Mathews CA et al (2013) Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study. Gynecol Oncol 130:12–18

    Article  PubMed  Google Scholar 

  21. Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W et al (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advances epitheliasl ovarian carcinoma: upfront therapy, at first recurrence or later? Eur J Surg Oncol 39:1109–1115

    Article  CAS  PubMed  Google Scholar 

  22. Chan DL, Morris DL, Rao A, Chua TC (2012) Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res 4:413–422

    PubMed Central  PubMed  Google Scholar 

  23. Di Giorgio A, Naticchioni E, Biacchi D et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315–325

    Article  PubMed  Google Scholar 

  24. Loggie BW, Sterchi JM, Rogersetal AT (1995) Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. Regional Cancer Treatment 7:78–81

    Google Scholar 

  25. Rufian S, Munoz-Casares FC, Briceno J et al (2006) Radical surgery—peritonectomy and in-tra-operative intra- peritoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. Journal of Surgical Oncology 94:316–324

    Article  PubMed  Google Scholar 

  26. Deraco M, Kusomura S, Virzi S et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as up front therapy for advanced. EOC: multi-institutional phase II study. Gynecologic Oncology 122:215–220

    Article  PubMed  Google Scholar 

  27. Ma DY, Tan BX, Li XF et al (2013) A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarianc cancer FIGO stage III and IV. World J Surg Oncol 11:267–271

    Article  Google Scholar 

  28. Sehouli J, Sawatis K, Braicu EI et al (2010) Primary versus interval debulking surgery in advanced ovarian cancer: results from a systemic single-center analysis. Int J Gynecol Cancer 20:1331–1340

    PubMed  Google Scholar 

  29. Helm CW, Richard SD, Pan J et al (2010) HIPEC in ovarian cancer: first report of HYPER-O registry. International Journal of Gynecological Cancer 20:61–69

    Article  PubMed  Google Scholar 

  30. Ryu KS, Kim JH, Ko HS et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94:325–332

    Article  CAS  PubMed  Google Scholar 

  31. http://clinicaltrials.gov/ct2/results?term=NCT01628380&Search=SearchNCT01628380

    Google Scholar 

  32. Fagotti A, Costantini B, Vizzielli G et al (2011) HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 122:221–225

    Article  PubMed  Google Scholar 

  33. Carrabin N, Mithieux, Meeus P et al (2010) Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull. Du Cancer 97:E23–32

    CAS  Google Scholar 

  34. Helm CW, Randall-Whitis L, Martin RS et al (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105:90–96

    Article  CAS  PubMed  Google Scholar 

  35. Cotte E, Glehen O, Mohamed F et al (2007) Cytoreductive surgery and intraperitoneal chemohyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 31:1813–1820

    Article  PubMed  Google Scholar 

  36. Ansaloni L, Agnoletti V, Amadori A et al (2012) Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. J Gynecol Cancer 22:778–785

    Article  Google Scholar 

  37. Roviello F, Marrelli D, de Manzoni G et al (2003) Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 90:1113–1119

    Article  CAS  PubMed  Google Scholar 

  38. Sugarbaker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope of cure. Oncology 58:96–107

    Article  CAS  PubMed  Google Scholar 

  39. Hultman B, Lind P, Glimelius B et al (2013) Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy. Acta Oncol 52:824–830

    Article  PubMed  Google Scholar 

  40. Costa WL, Coimbra FJ, Ribeiro FS et al (2012) Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol 10:195

    Article  PubMed Central  PubMed  Google Scholar 

  41. Müller H, Hotopp TH, Tofeili A, Wutke K Systemic chemotherapy using FLOT - regimen combined with cytoreductive surgery plus hipec for treatment of peritoneal metastasized gastric cancer. http://www.onkochirurgie.de/content/public/local/systemic_chemotherapy_using_flot.html

    Google Scholar 

  42. Yonemura Y, Elnemr A, Endou Y et al (2012) Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol 2012:148420

    PubMed Central  PubMed  Google Scholar 

  43. Yonemura Y, Elnemr A, Endou Y et al (2010) Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2:85–97

    Article  PubMed Central  PubMed  Google Scholar 

  44. Yu W, Whang I, Chung HY et al (2001) Indications for earl postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25:985–990

    Article  CAS  PubMed  Google Scholar 

  45. Yan TD, Black D, Sugarbaker PH et al (2007) A systematic review and metaanalysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713

    Article  PubMed  Google Scholar 

  46. Hamazoe R, Maeta M, Kaibara N (1994) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73:2048–2052

    Article  CAS  PubMed  Google Scholar 

  47. Yonemura Y, de Aretxabala X, Fujimura T et al (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 48:1776–1782

    CAS  PubMed  Google Scholar 

  48. Minsky BD, Mies C, Rich TA et al (1988) Potentially curative surgery of colon cancer: Patterns of failure and survival. J Clin Oncol 6:106–118

    CAS  PubMed  Google Scholar 

  49. Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  50. Elias D, Delperro JR, Sideris L et al (2004) Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 11:518–521

    Article  PubMed  Google Scholar 

  51. Avital I, Brucher BL, Nissan A, Stojadinovic A (2012) Randomized clinical trials for colorectal cancer Peritoneal carcinomatosis and peritoneal surface malignancy. Surg Oncol Clin N Am 21:665–688

    Article  PubMed  Google Scholar 

  52. Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68

    Article  PubMed  Google Scholar 

  53. Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685

    Article  PubMed  Google Scholar 

  54. Chua TC, Morris DL, Saxena A et al (2011) Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 18:1560–1567

    Article  PubMed  Google Scholar 

  55. Riss S, Mohamed S, Dayal S et al (2013) Peritoneal metastases from colorectal cancer : patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 39:931–937

    Article  CAS  PubMed  Google Scholar 

  56. Rivard JD, McConnell YJ, Temple WJ, Mack LA (2014) Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: Are we excluding patients who may benefit? J Surg Oncol 109:104–109

    Article  PubMed  Google Scholar 

  57. Glockzin G, Rochon J, Arnold D et al (2013) A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 13:67

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Miller J, Wynn H (1908) A malignant tumor arising from the endothelium of the peritoneum and producing a mucoid ascitic fluid. J Pathol Bacteriol 12:267

    Article  Google Scholar 

  59. Chailleux E, Dabouis G, Pioche D et al (1988) Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 93:159–162

    Article  CAS  PubMed  Google Scholar 

  60. Eltabbakh GH, Piver MS, Hempling RE et al (1999) Clinical picture, response to therapy,and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6–12

    Article  CAS  PubMed  Google Scholar 

  61. Yan TD, Welch L, Black D et al (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–834

    Article  CAS  PubMed  Google Scholar 

  62. Yan TD, Deraco M, Baratti D (2009) Cytoreductive surgery and hyperthermic intra- peritoneal chemotherapy for malignant peritoneal mesothelioma: multi- institutional experience. J Clin Oncol 27:6237e42

    Google Scholar 

  63. Deraco M, Baratti D, Hatanu I et al (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20:1093–1100

    Article  PubMed  Google Scholar 

  64. Smeenk RM, van Velthuysen ML, Verwaal VJ et al (2008) Appendiceal neo- plasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 34:196–201

    Article  CAS  PubMed  Google Scholar 

  65. Gough DB, Donohue JH, Schutt AJ et al (1994) Pseudomyxoma peritonei: long-term patient survival with an aggressive regional approach. Ann Surg 219:112e9.

    Article  Google Scholar 

  66. Yan TD, Black D, Savady R et al (2007) A sistematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–492

    Article  PubMed  Google Scholar 

  67. Deraco MI, Kusamura S, Laterza B et al (2006) Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. In Vivo 20:773–776

    CAS  PubMed  Google Scholar 

  68. Chua TC, Moran BJ, Sugarbaker PH (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyper- thermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Oncology, and Human Pathology, Sapienza University of Rome, Rome, Italy

    Patrizia Trenta

Authors
  1. Patrizia Trenta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Giovannoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emanuela Risi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enrico Cortesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrizia Trenta .

Editor information

Editors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Angelo Di Giorgio

  2. Department of Medical, Surgical, and Neurological Sciences, University of Siena, Siena, Italy

    Enrico Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Trenta, P., Giovannoni, S., Risi, E., Cortesi, E. (2015). The Role of Systemic Chemotherapy. In: Di Giorgio, A., Pinto, E. (eds) Treatment of Peritoneal Surface Malignancies. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5711-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5711-1_12

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5710-4

  • Online ISBN: 978-88-470-5711-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation